Certified by Founder
Lodge
BioLoomics, Inc.
start up
United States
- Boulder, CO
- 20/09/2023
- Seed
- $8,700,000
BioLoomics is a preclinical stage biotechnology company leveraging directed evolution of antibodies in human cells to create target degrading antibodies. Our proprietary tech combines single-cell bioassay engineering, robotics, and ML.
#synbio #directedevolution #antibodies
- Industry Biotechnology Research
- Website https://www.bioloomics.com/
- LinkedIn https://www.linkedin.com/company/bioloomics/about/
Zócalo Health | $15,000,000 | (Apr 24, 2026)
Rilian | $17,500,000 | (Apr 24, 2026)
BAND | $17,000,000 | (Apr 24, 2026)
Brev.io | $3,300,000 | (Apr 24, 2026)
Maxed | $850,000 | (Apr 24, 2026)
Omni | $120,000,000 | (Apr 24, 2026)
VREY | $3,859,432 | (Apr 24, 2026)
Astor (YC S25) | $5,000,000 | (Apr 24, 2026)
QMatter | $1,200,000 | (Apr 24, 2026)
Almanac Health | $10,000,000 | (Apr 24, 2026)
Petual | $20,000,000 | (Apr 24, 2026)
C-Infinity | $16,000,000 | (Apr 23, 2026)